Cite
HARVARD Citation
Ong-Lim, A. et al. (2022). Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age. Human vaccines & immunotherapeutics. 18 (5), p. . [Online].